文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

实体瘤CAR-T细胞疗法的全球研究趋势:一项全面的可视化和文献计量研究(2012 - 2023年)

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012-2023).

作者信息

Miao Lele, Zhang Juan, Xu Wei, Qian Qian, Zhang Guochao, Yuan Quan, Lv Yuetao, Zhang Haiguo, Shen Chaoyan, Wang Wei

机构信息

Department of Thyroid and Breast Surgery, Jining NO.1 People's Hospital, Jining, China.

Department of Hematology, Jining NO.1 People's Hospital, Jining, China.

出版信息

Hum Vaccin Immunother. 2024 Dec 31;20(1):2338984. doi: 10.1080/21645515.2024.2338984. Epub 2024 May 2.


DOI:10.1080/21645515.2024.2338984
PMID:38698555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11073418/
Abstract

CAR-T cell therapy has emerged as a significant approach for the management of hematological malignancies. Over the past few years, the utilization of CAR-T cells in the investigation and treatment of solid tumors has gained momentum, thereby establishing itself as a prominent area of research. This descriptive study involved the retrieval of articles about CAR-T cell therapy for solid tumors from the Web of Science Core Collection (WoSCC) database. Subsequently, bibliometric analysis and knowledge map analysis were conducted on these articles. The field under consideration is currently experiencing a period of swift advancement, as evidenced by the escalating number of publications in this domain each year. The United States holds an indisputable position as the foremost leader in this particular field, with the University of Pennsylvania emerging as the most active institution. The authors with the highest citation frequency and co-citation frequency are Carl H. June and Shannon L. Maude, respectively. The research hotspots in this field mainly focus on five aspects. Additionally, 10 emerging themes were identified. This study undertakes a comprehensive, systematic, and objective analysis and exploration of the field of CAR-T cell treatment for solid tumors, utilizing bibliometric methods. The findings of this study are expected to serve as a valuable reference and enlightenment for future research endeavors in this particular domain.

摘要

嵌合抗原受体T细胞(CAR-T)疗法已成为治疗血液系统恶性肿瘤的一种重要方法。在过去几年中,CAR-T细胞在实体瘤研究和治疗中的应用势头渐强,从而成为一个突出的研究领域。这项描述性研究涉及从科学引文索引核心合集(WoSCC)数据库中检索有关CAR-T细胞治疗实体瘤的文章。随后,对这些文章进行了文献计量分析和知识图谱分析。鉴于该领域每年发表的文章数量不断增加,目前正处于快速发展阶段。美国在这一特定领域占据无可争议的领先地位,宾夕法尼亚大学是最活跃的机构。被引频次最高和共被引频次最高的作者分别是卡尔·H·朱恩(Carl H. June)和香农·L·莫德(Shannon L. Maude)。该领域的研究热点主要集中在五个方面。此外,还确定了10个新兴主题。本研究利用文献计量方法,对实体瘤CAR-T细胞治疗领域进行了全面、系统和客观的分析与探索。预计本研究结果将为该特定领域未来的研究工作提供有价值的参考和启示。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/b6ecd9b68b55/KHVI_A_2338984_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/6340088326ef/KHVI_A_2338984_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/e9a19f83e0d0/KHVI_A_2338984_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/01eb8e6cd9bc/KHVI_A_2338984_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/01b55aa6bab3/KHVI_A_2338984_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/a92d3a9520dc/KHVI_A_2338984_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/3b5a941a11dc/KHVI_A_2338984_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/b6ecd9b68b55/KHVI_A_2338984_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/6340088326ef/KHVI_A_2338984_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/e9a19f83e0d0/KHVI_A_2338984_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/01eb8e6cd9bc/KHVI_A_2338984_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/01b55aa6bab3/KHVI_A_2338984_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/a92d3a9520dc/KHVI_A_2338984_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/3b5a941a11dc/KHVI_A_2338984_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2821/11073418/b6ecd9b68b55/KHVI_A_2338984_F0007_OC.jpg

相似文献

[1]
Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012-2023).

Hum Vaccin Immunother. 2024-12-31

[2]
A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023.

Hum Vaccin Immunother. 2024-12-31

[3]
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

Front Immunol. 2022

[4]
A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.

Front Immunol. 2022

[5]
Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.

Front Immunol. 2022

[6]
Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis.

Hum Vaccin Immunother. 2023-12-15

[7]
A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.

Hum Vaccin Immunother. 2023-12-15

[8]
Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023.

Hum Vaccin Immunother. 2024-12-31

[9]
Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.

Int J Clin Pharm. 2024-2

[10]
Global research trends and focus on immunotherapy for endometrial cancer: a comprehensive bibliometric insight and visualization analysis (2012-2024).

Front Immunol. 2025-4-8

引用本文的文献

[1]
Can We Use CAR-T Cells to Overcome Immunosuppression in Solid Tumours?

Biology (Basel). 2025-8-12

[2]
Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015-2024).

Discov Oncol. 2025-8-3

[3]
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.

Curr Issues Mol Biol. 2025-4-10

[4]
Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction.

Cell Insight. 2025-5-12

[5]
The global trend of intravenous anesthesia and tumors: a bibliometric and visualized study.

Perioper Med (Lond). 2025-3-17

[6]
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.

Biomark Res. 2025-3-11

[7]
Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis.

Hum Vaccin Immunother. 2025-12

[8]
Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research.

Naunyn Schmiedebergs Arch Pharmacol. 2024-12

本文引用的文献

[1]
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro.

Exp Hematol Oncol. 2023-10-6

[2]
The application of HER2 and CD47 CAR-macrophage in ovarian cancer.

J Transl Med. 2023-9-22

[3]
ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype.

Front Oncol. 2023-8-18

[4]
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.

J Hematol Oncol. 2023-9-9

[5]
Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.

Cell Immunol. 2023

[6]
Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments.

Chin Med J (Engl). 2024-6-5

[7]
Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.

Exp Hematol Oncol. 2023-8-21

[8]
B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers.

Front Oncol. 2023-7-7

[9]
Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.

Cancers (Basel). 2023-5-15

[10]
Time to abandon CAR-T monotherapy for solid tumors.

Biochim Biophys Acta Rev Cancer. 2023-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索